New oral gel could tame tough tumors with fewer side effects
NCT ID NCT06143774
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an oral gel called TRX-920 in 30 people with advanced solid tumors that no longer respond to standard treatments. The gel contains SN38, a powerful anti-cancer drug, and aims to shrink tumors with fewer side effects than the current IV version. The main goals are to find the safest dose and check how well the body tolerates it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Medical University Hospital
RECRUITINGTaichung, Taiwan
-
National Cheng-Kung University Hospital
RECRUITINGTainan, Taiwan
-
Taipei Medical University Hospital
RECRUITINGTaipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Can a new drug shrink Hard-to-Treat tumors?
- Can a Custom-Made immune cell vaccine turn the tide against solid tumors?